Back grey_arrow_rt.gif
Boehringer Ingelheim Launches Co-Pay Rebate Program for Viramune
  Viramune Co-Pay Savings Program Allows Immediate Rebate Authorization at Point-of-Purchase with MasterCard Debit Card*
Ridgefield, CT, October 6, 2009 -Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of the Viramune® (nevirapine) tablets/oral suspension Co-Pay Savings Program, a special program that will allow patients to save up to $50 on their health insurance co-payment on every monthly refill of a VIRAMUNE prescription for up to one year. Any patient with a VIRAMUNE prescription who has health insurance coverage requiring a patient co-payment is eligible for the program.
A valuable feature of the program is the use of a MasterCard® debit card that is solely dedicated to the purchase of a VIRAMUNE prescription, which can be used at any pharmacy that accepts MasterCard. The up to $50 rebate will be credited to the patient at the point-of-purchase as quickly as any MasterCard transaction.
"There is a growing reliance by patients on co-pay and patient assistance programs offered by pharmaceutical companies and this rebate program makes it easier for HIV/AIDS patients to benefit," said Albert Ros, executive vice president of Sales and Marketing, Boehringer Ingelheim Pharmaceuticals, Inc."Initiatives to ease the financial burden of health insurance co-payment for HIV/AIDS patients such as this one underscore our commitment to helping patients obtain the care and treatment they need."
Patients can obtain the VIRAMUNE Co-Pay Savings Card through their healthcare providers. Patients need to activate their card by calling a toll-free hotline at 1-888-99-VIRAMUNE (1-888-998-4726) or logging onto
In addition, as part of the activation process patients can also enroll to receive free educational information and support from the Vlife on Therapy program.
Once activated, the VIRAMUNE Co-Pay Savings Card can be presented, together with a VIRAMUNE prescription, at any pharmacy that accepts MasterCard. The card will immediately deduct up to $50 from the co-payment for VIRAMUNE.
The VIRAMUNE Co-Pay Savings Card will also be accepted at mail order pharmacies.
Boehringer Ingelheim Patient Assistance Program
Boehringer Ingelheim is committed to ensuring that patients who need VIRAMUNE have access to the medication. The Boehringer Ingelheim Cares Foundation Patient Assistance Program (BI PAP) provides Boehringer Ingelheim medications free of charge to eligible patients in financial need, including those without prescription drug coverage and low-income Medicare beneficiaries. Patients in need of Viramune® (nevirapine) tablets/oral suspension should call 800-556-8317 to speak with a program representative or visit for information about the BI PAP including eligibility criteria and program applications.
VIRAMUNE Important Safety Information
VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.
VIRAMUNE does not cure HIV or AIDS, and has not been shown to reduce the risk of passing HIV to others through sexual contact or blood contamination.
VIRAMUNE can cause severe liver disease and skin reactions that can cause death. These reactions occur most often during the first 18 weeks of treatment, but can occur later. Patients need to ask their HCP about how to recognize symptoms of skin and liver problems. VIRAMUNE should be discontinued and not restarted in patients who have any of these reactions.
Any patient can experience liver problems with VIRAMUNE, but women and patients who have higher CD4+ counts when they begin VIRAMUNE treatment have a greater risk. A woman with CD4+ >250 cells/mm3, or a man with CD4+ >400 cells/mm3 should not begin taking VIRAMUNE unless they and their HCP have decided that the benefit of doing so outweighs the risk. Women, including pregnant women, with CD4+ cell counts >250 cells/mm3 are at the greatest risk.
Do not take VIRAMUNE if you have severe liver problems.
The dose of VIRAMUNE for adults is one 200-mg tablet daily for the first 14 days, followed by one 200-mg tablet twice daily. VIRAMUNE is always taken with other anti-HIV medications. The 14-day lead-in period is important because it can help reduce your chances of getting a potentially serious skin rash. Patients who have a skin rash during the first 14 days should immediately contact their HCP and not increase their VIRAMUNE dose to twice a day. The total duration of the once-daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started.
Other side effects that patients have experienced include nausea, fatigue, fever, headache, vomiting, diarrhea, abdominal pain, and myalgia. Changes in body fat may occur in patients receiving antiretroviral therapy. Immune reconstitution syndrome has been reported in patients treated with combination ARV therapy.
Please see full Prescribing Information, including boxed WARNING, for
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit
* MasterCard® and the MasterCard Brand Mark are registered trademarks of MasterCard International Incorporated.
  icon paper stack View Older Articles   Back to Top